Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Jennifer D. Byrne, LCSW, CADC, Katie S. Clancy, MSW, and Isabell Ciszewski, LCSW
Social work perspectives on whether prescribers should authorize opioid refills emphasize the importance of multidisciplinary approaches to patient self-determination.
AMA J Ethics. 2020;22(8):E658-663. doi:
10.1001/amajethics.2020.658.
Considering chronic opioid use when planning elective surgery would likely enhance team communication, decrease stigma, and facilitate care transitioning and long-term planning.
AMA J Ethics. 2020;22(8):E664-667. doi:
10.1001/amajethics.2020.664.
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.
Dr Laura Kolbe joins Ethics Talk to discuss her article, coauthored with Drs Ryan H. Nelson, Joelle Robertson-Preidler, Olivia Schuman, and Inmaculada de Melo-Martín: “Is a Video Worth a Thousand Words?”